Canada markets closed

AMRN Jul 2024 0.500 put

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
0.05000.0000 (0.00%)
As of 09:46AM EDT. Market open.
Full screen
Previous Close0.0500
Expire Date2024-07-19
Day's Range0.0500 - 0.1200
Contract RangeN/A
Open Interest59
  • GlobeNewswire

    Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal

    -- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD)1 -- -- Approval marks eighth national reimbursement of VAZKEPA® in Europe -- DUBLIN, Ireland and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announces that the Portuguese Ministry of Health has approved VAZKEPA® (icosapent ethyl) for national re

  • GlobeNewswire

    Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024

    DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed by Q&A on Wednesday, July 31st, 2024, at 8:00 a.m. ET. The conference call with management will follow the release of the Company’s second quarter 2024 financial results in the pre-market hours on July 31st. To enh

  • GlobeNewswire

    Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)

    -- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- -- EddingPharm Now Working to Prepare for National Reimbursement and Drug Listing (NRDL) and Enhance the Commercial Launch of VASCEPA Across Mainland China -- DUBLIN and BRIDGEWATER, N.J., July 08, 2024 (GLOBE NEWSWI